An Open Multicenter Study of the Safety, Tolerability, and Pharmacokinetics of Different Doses of Stimotimagene Copolymerplasmid at Patients With Advanced-stage Solid Tumors With Cymeven® (Ganciclovir) Infusions

Study Summary

The purpose of this study is to evaluate the safety and tolerability of different doses and administration regimens of Stimotimagene copolymerplasmid in patients with histologically confirmed diagnosis of solid tumor and/or its metastases.

Interventions

Study Locations

Facility	City	State	Country
GBUZ Moscow Clinical Scientific Center named after Loginov MHD	Moscow		Russia
FSBI N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia	Moscow		Russia
FSBI National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov of the Ministry of Health of Russia	Moscow		Russia
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation	Moscow		Russia

Official Trial Information

View on ClinicalTrials.gov